Amgen Reports Q1 2026 Earnings with Mixed Performance Across Product Lines
Amgen (AMGN) reported Q1 2026 earnings with total product sales increasing 4% year-over-year, driven by growth in several key products. However, some products like Prolia and XGEVA faced declines due to exclusivity losses. The company highlighted strong performance in Repatha, Evenity, and its rare disease portfolio.
Tickers: $AMGN
Topics: earnings financial results product performance sales growth